

REFERENTIES

1. A. Cannabinoid pharmacology in cancer research: A new hope for cancer patients? Javid FA, Phillips RM, Afshinjavid S, et al. *Ligresti Eur J Pharmacol.* 2016; 775:1–14.
2. Role of cannabinoid receptor CB2 in HER2 pro-oncogenic signaling in breast cancer. Perez-Gomez E, Andradas C, Blasco-Benito S, et al. *J Natl Cancer Inst.* 2015;107(6): djv077.
3. Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition. Caffarel MM, Andradas C, Mira E, et al. *Mol Cancer.* 2010;9: 196.
4. A high cannabinoid CB1 receptor immunoreactivity is associated with disease severity and outcome in prostate cancer. Chung SC, Hammarsten P, Josefsson A, et al. *Eur J Cancer.* 2009;45(1):174–82.
5. Fatty acid amide hydrolase in prostate cancer: association with disease severity and outcome, CB1 receptor expression and regulation by IL-4. Thors L, Bergh A, Persson E, et al. *PLoS One.* 2010;5(8): e12275.
6. Cannabinoids for cancer treatment: progress and promise. Sarfaraz S, Adhami VM, Syed DN, et al. *Cancer Res.* 2008;68(2):339–42.
7. Proapoptotic effect of endocannabinoids in prostate cancer cells. Orellana-Serradell O, Poblete CE, Sanchez C, et al. *Oncol Rep.* 2015;33(4):1599–1608.
8. Expression of the transient receptor potential vanilloid 1 (TRPV1) in LNCaP and PC-3 prostate cancer cells and in human prostate tissue. Sanchez MG, Sanchez AM, Collado B, et al. *Eur J Pharmacol.* 2005;515(1-3):20–7.
9. Activation of endogenous TRPV1 fails to induce overstimulation-based cytotoxicity in breast and prostate cancer cells but not in pain-sensing neurons. Pecze L, Josvay K, Blum W, et al. *Biochim Biophys Acta.* 2016;1863(8):2054–64.
10. Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms. De Petrocellis L, Ligresti A, Schiano Moriello A, et al. *Br J Pharmacol.* 2013;168(1):79–102.
11. Cannabinoid receptor 1 promotes hepatocellular carcinoma initiation and progression through multiple mechanisms. Mukhopadhyay B, Schuebel K, Mukhopadhyay P, et al. *Hepatology.* 2015;61(5):1615–26.
12. Cannabinoids in pancreatic cancer: correlation with survival and pain. Michalski CW, Oti FE, Erkan M, et al. *Int J Cancer.* 2008;122(4):742–50.
13. Cannabinoids as therapeutic agents in cancer: current status and future implications. Chakravarti B, Ravi J, Ganju RK. *Oncotarget.* 2014;5(15):5852–72.
14. Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes. Carracedo A, Gironella M, Lorente M, et al. *Cancer Res.* 2006;66(13):6748–55.
15. Cannabinoid receptor 2 is upregulated in melanoma. Zhao Z, Yang J, Zhao H, et al. *J Cancer Res Ther.* 2012;8(4):549–54.
16. Update on the endocannabinoid system as an anticancer target. Malfitano AM, Ciaglia E, Gangemi G, et al. *Expert Opin Ther Targets.* 2011;15(3):297–308.
17. Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Nomura DK, Long JZ, Niessen S, Hoover HS, Ng SW, Cravatt BF. *Cell.* 2010;140(1):49–61.
18. Endocannabinoids and cancer. Velasco G, Sanchez C, Guzman M. *Handb Exp Pharmacol.* 2015; 231:449–72.
19. Cannabinoid signalling. Demuth DG, Molleman A. *Life Sci.* 2006;78(6):549–63.
20. Anticancer mechanisms of cannabinoids. Velasco G, Sanchez C, Guzman M. *Curr Oncol.* 2016;23(Suppl 2): S23–S32.
21. Cannflavin A and B, prenylated flavones from *Cannabis sativa* L. M.L. Barrett, A.M. Scutt and F.J. Evans *Experientia* 42 (1986), Birkhäuser Verlag, CH-4010 Basel/Switzerland.
22. Isolation from *Cannabis Sativa* L. Of Cannflavin - A novel inhibitor of prostaglandin production. M.L. Barrett, D. Gordon and F.J. Evans. *Biochemical Pharmacology.* Vol. 34. No. 11. pp. 2019-2024. 1985.

23. Cyclooxygenases, prostanoids, and tumor progression. Man-Tzu Wang, Kenneth V. Honn, Daotai Nie. *Cancer Metastasis Rev* (2007) 26:525–534.
24. Hasan S, Satake M, Dawson DW, et al. Expression analysis of the prostaglandin E2 production pathway in human pancreatic cancers. *Pancreas*. 2008; 37:121–127.
25. Microsomal prostaglandin E synthase-1 and 5-lipoxygenase: potential drug targets in cancer. O. Rådmark & B. Samuelsson. 2010 Blackwell Publishing Ltd *Journal of Internal Medicine* 268; 5–14.
26. A review on mPGES-1 inhibitors: From preclinical studies to clinical applications. Filip Bergqvist, Ralf Morgenstern, Per-Johan Jakobsson. *Prostaglandins and Other Lipid Mediators* 147 (2020) 106383, 1-11.
27. Cannflavins from hemp sprouts, a novel cannabinoid-free hemp food product, target microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase Oliver Werz, Julia Seegers, Anja Maria Schaible, et al.
28. Flavonoid Derivative of Cannabis Demonstrates Therapeutic Potential in Preclinical Models of Metastatic Pancreatic Cancer. Michele Moreau, Udoka Ibeh, Kaylie Decosmo et al. July 2019, Volume 9. Article 660. 1-9.
29. Probing the Pharmacological Binding Properties, and Reactivity of Selective Phytochemicals as Potential HIV-1 protease Inhibitors. Ammara Akhtar¹, Waqar Hussain², Nouman Rasool, et al. *Univ. Sci.* 24 (3): 441-464, 2019.
30. Novel cannabis flavonoid, cannflavin A displays both a hormetic and neuroprotective profile against amyloid β -mediated neurotoxicity in PC12 cells: Comparison with geranylated flavonoids, mimulone and diplacone. Carly Eggers, Masaya Fujitani, Ryuji Kato et al. *Biochemical Pharmacology* 169 (2019) 113609.
31. Non-cannabinoid constituents from a high potency Cannabis sativa variety. Mohamed M. Radwan, Mahmoud A. ElSohly, Desmond Slade. *Phytochemistry* 69 (2008) 2627–2633.
32. What is the Molecular Signature of Mind–Body interventions? A Systematic Review of Gene expression. Changes induced by Meditation and Related Practices. Ivana Buric, Miguel Farias, Jonathan Jong. *Frontiers in Immunology. Gene Expression and Mind-Body Interventions*. June 2017, Volume 8; Article 670. 1-17.